Enterprise record

Alvotech

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassing autoimmune conditions, eye disorders, bone diseases, and cancer. A flagship program for the company is AVT02, a high-concentration biosimilar equivalent to Humira. This candidate is designed to address a range of inflammatory illnesses, including rheumatoid arthritis, psoriatic arthritis, Crohn's

Follow
More
Reports & analysis (Directory temporarily unavailable)Alpha EvalSave PDFCompareChallenge a ClaimClaim this record

Alpha ID: alpha:company:548f755d-f67b-4e61-8582-ba1f98fa3f9dVersion: public-1As of: unavailable

6 published Claims1 sources

Key Claims

Source-backed public-market identity

Index memberships

Current memberships are attached to a specific security and listing. Announcements, effective dates, and removals remain distinct states; Alpha does not infer membership from company size, exchange, or reputation.

No current membership is published in Alpha's tracked index universe.

This is not evidence that the company is absent from every market index.

As of Sep 28, 2026. Rights-filtered public evidence only; no redistribution or model training is granted.

Only source-backed memberships with an explicit public redistribution basis are returned.

Evidence, history and coverage

Additional published Claims

Published evidence records

1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. Alpha canonical company public projection

    canonical identity · Source published: Date unavailable · Retrieved: Sep 28, 2026

    Supports 6 claims
    • Legal Name: Alvotech · Claim reviewed: Sep 28, 2026
    • Entity Status: Public listing published · Claim reviewed: Sep 28, 2026
    • Published Fact: US · Claim reviewed: Sep 28, 2026
    • Published Fact: SE · Claim reviewed: Sep 28, 2026
    • Published Fact: Healthcare · Claim reviewed: Sep 28, 2026
    • Published Fact: Drug Manufacturers - Specialty & Generic · Claim reviewed: Sep 28, 2026